These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2877853)

  • 1. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.
    Farr M; Scott DG; Bacon PA
    Drugs; 1986; 32 Suppl 1():49-53. PubMed ID: 2877853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Ransford RA; Langman MJ
    Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.
    Capell HA; Pullar T; Hunter JA
    Drugs; 1986; 32 Suppl 1():44-8. PubMed ID: 2877852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
    Pullar T; Capell HA
    Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results.
    Georgescu C
    Rom J Intern Med; 1992; 30(2):127-32. PubMed ID: 1353901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
    Mundo A; Pedone V; Lamanna G; Cervini C
    Clin Ter; 1997; 148(1-2):7-13. PubMed ID: 9377840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
    Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
    Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study.
    Donovan S; Hawley S; MacCarthy J; Scott DL
    Br J Rheumatol; 1990 Jun; 29(3):201-4. PubMed ID: 1972633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.
    Amos RS; Pullar T; Bax DE; Situnayake D; Capell HA; McConkey B
    Br Med J (Clin Res Ed); 1986 Aug; 293(6544):420-3. PubMed ID: 2874863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids.
    Gran JT; Myklebust G
    Scand J Rheumatol; 1993; 22(5):229-32. PubMed ID: 7901898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis.
    Wijnands MJ; Van 'T Hof MA; Van De Putte LB; Van Riel PL
    Br J Rheumatol; 1993 Apr; 32(4):313-8. PubMed ID: 8096419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term outcome of treatment with sulphasalazine in rheumatoid arthritis.
    Situnayake RD; McConkey B
    Drugs; 1986; 32 Suppl 1():71-2. PubMed ID: 2877857
    [No Abstract]   [Full Text] [Related]  

  • 14. Sulphasalazine in the long term management of rheumatoid arthritis.
    Bax DE; Amos RS
    Drugs; 1986; 32 Suppl 1():73-6. PubMed ID: 2877858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.
    Farr M; Symmons DP; Blake DR; Bacon PA
    Ann Rheum Dis; 1986 Sep; 45(9):761-4. PubMed ID: 2876683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis.
    van Riel PL; van Gestel AM; van de Putte LB
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():40-2. PubMed ID: 8535648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of non-steroidal anti-inflammatory drug induced enteropathy.
    Bjarnason I; Hopkinson N; Zanelli G; Prouse P; Smethurst P; Gumpel JM; Levi AJ
    Gut; 1990 Jul; 31(7):777-80. PubMed ID: 1973396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages.
    Wilkieson CA; Madhok R; Hunter JA; Capell HA
    Q J Med; 1993 Aug; 86(8):501-5. PubMed ID: 8105504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
    Laversuch CJ; Collins DA; Charles PJ; Bourke BE
    Br J Rheumatol; 1995 May; 34(5):435-9. PubMed ID: 7788172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.